Target intelligence / Profile preview

T cell receptor alpha variable 12-2 (TRAV12-2)

Target
TRAV12-2
Molecular classification
Receptor, Immunoglobulin superfamily (IG-like domain/V gene), T cell receptor variable segment
01

Overview

T cell receptor alpha variable 12-2 encodes the variable domain of the alpha chain in certain T cell receptors, which are essential for the antigen recognition that sparks adaptive immune responses. TCRs are comprised of paired alpha and beta chains (or gamma and delta), and TRAV12-2 contributes to the diversity and specificity of peptide-MHC recognition on antigen-presenting cells. TRAV12-2 use is biased in TCRs recognizing specific antigens (e.g., A2/ELA from Melan-A/MART-1 and A2/Tax from HTLV-1). The germline-encoded CDR1α loop of TRAV12-2 makes major contacts with peptide-MHC complexes, influencing the frequency and prevalence of naïve T cells with this specificity. Variation in TRAV12-2 is relevant to disease-specific immune responses, particularly in cancer and viral infections[1][2][3][4].

Other names
TRAV12-2TCRAV12S2TCRAV2S1TRAV122
02

Mechanism of action

Drugs acting on T cell receptors (not specific for TRAV12-2) function via modulation of antigen recognition, T cell activation, or immune checkpoint inhibition. They leverage TCR signaling to enhance or suppress immune responses, but TRAV12-2 specificity is relevant in adoptive T cell therapies targeting specific antigens[4].

03

Biological functions

Immune responseAntigen recognitionSignal transductionT cell selection and activation
04

Disease associations

Cancer (e.g., melanoma antigen-specific T cell responses)Infection (e.g., viral epitopes HTLV-1, vaccine antigens like YF-17D)Inflammation (through regulation of CD8^+^ T cell responses)
05

Safety considerations

TRAV12-2 itself does not present unique safety concerns, but therapies that alter TCR repertoires may result in off-target effects, autoimmunity, or cytokine release syndrome. No specific issues are attributed to TRAV12-2
06

Interacting drugs

Checkpoint inhibitors

1 more in the full profile.

07

Biomarkers

TRAV12-2 usage is a biomarker for epitope-specific CD8^+^ T cell responses, notably in melanoma (Melan-A/MART-1 antigen) and following certain vaccinations (YF-17D)

Beyond the preview

Go deeper on T cell receptor alpha variable 12-2 (TRAV12-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha variable 12-2 (TRAV12-2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call